Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.
CITATION STYLE
Alder, L., Trapani, D., Bradbury, C., Van Swearingen, A. E. D., Tolaney, S. M., Khasraw, M., … Sammons, S. (2023). Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. Npj Breast Cancer, 9(1). https://doi.org/10.1038/s41523-023-00519-0
Mendeley helps you to discover research relevant for your work.